Foto af cho cells

New strategic alliance between NBF and Bioneer A/S

Friday 24 Sep 21
|

Contact

Bjørn Gunnar Voldborg
Director Cell Line and Protein Production Facility
DTU Bioengineering
+45 21 12 61 91

The National Biologics Facility (NBF) and Bioneer A/S enters into a strategic collaboration with the aim of commercializing combined CRO services for mammalian expression of recombinant proteins.

Bioneer A/S, a globally operating Danish specialty-CRO creating and commercializing innovative research service solutions for early stage drug development and in vitro modelling, enters into a strategic alliance with NBF, which is one of the largest academic groups in the world working on Chinese Hamster Ovary cell (CHO) modelling and mechanisms.

NBF and Bioneer A/S complement each other’s capabilities. NBF brings broad experience in CHO cell line engineering and expert understanding of stable protein expression in CHO cells. Bioneer A/S brings nearly 40 years of commercial and scientific experience creating customized service solutions in the field of expression and production of special proteins and antibodies.

"I am extremely excited about the collaboration that will allow us to deploy the expertise, know-how, and infrastructure for protein and cell line development in mammalian cells we have generated over the past 8 years at DTU."
Bjørn Voldborg, Director at NBF

This collaboration will enable Bioneer to offer end-to-end non-GMP production of recombinant proteins utilizing both microbial and mammalian expression platforms, and Jette Asboe Lassen, CBO at Bioneer A/S, says: “We are excited to join forces with NBF and to be able to expand our offering and capacity to clients seeking mammalian cell line development and production capabilities for recombinant proteins.”

Bjørn Voldborg, Director at NBF, adds: “I am extremely excited about this collaboration that will allow us to deploy the expertise, know-how, and infrastructure for protein and cell line development in mammalian cells we have generated over the past eight years at DTU.”

This collaboration between Bioneer A/S and NBF will be of benefit to the national and international biotech and pharma industries, in a climate where the global need for facilities dedicated to the development of biologically based therapeutics and specialty proteins is more important than ever.

About the National Biologics Facility

The National Biologics Facility (NBF) is one of the largest academic groups in the world working on Chinese Hamster Ovary cell (CHO) modelling and mechanisms. Funded by the Novo Nordisk Foundation, it was established in 2012 at the Technical University of Denmark (DTU) and is today part of DTU Bioengineering. We offer industrial and academically based expertise and uniquely customized services for the early discovery and developmental stages of protein-based therapeutics, from early drug discovery to pre-clinical development, using standard as well as more advanced in-house developed mammalian production systems. Our combined industrial and academic background enables us to provide innovative solutions for clients to reach their goals and improve and accelerate their projects towards clinical phases, manufacturing, and market. https://nbf.dtu.dk/

About Bioneer A/S

Bioneer A/S is a trusted strategic R&D partner to biotech and pharmaceutical companies operating globally. We are a specialty-CRO, creating customized and innovative research service solutions through our unique know-how and advanced technologies. As an extended R&D team for our clients, we help develop and produce early drug candidates and generate key pre-clinical insights into their mechanisms, efficacy, and safety. With dedicated and highly skilled employees, state-of-the-art laboratory facilities, and a history of nearly 40 years of operation, we deliver innovative solutions to the Life Science industry, as a Danish government-approved Research and Technology Organization. Read more: www.bioneer.dk

News and filters

Get updated on news that match your filter.